X
Xuntian Jiang
Researcher at Washington University in St. Louis
Publications - 57
Citations - 2686
Xuntian Jiang is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Galactosylceramidase & Cholesterol storage. The author has an hindex of 23, co-authored 57 publications receiving 2005 citations. Previous affiliations of Xuntian Jiang include University of Washington.
Papers
More filters
Journal ArticleDOI
Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex
Brian M. Castellano,Ashley M. Thelen,Ofer Moldavski,McKenna Feltes,Reini E. N. van der Welle,Laurel Mydock-McGrane,Xuntian Jiang,Robert J. van Eijkeren,Oliver B. Davis,Sharon M. Louie,Rushika M. Perera,Douglas F. Covey,Daniel K. Nomura,Daniel S. Ory,Roberto Zoncu +14 more
TL;DR: Cholesterol is identified, an essential building block for cellular growth, as a nutrient input that drives mTORC1 recruitment and activation at the lysosomal surface and the SLC38A9-NPC1 complex, which is key to the ability of m TORC1 to respond to variations in dietary lipid supply.
Journal ArticleDOI
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial
Daniel S. Ory,Elizabeth A. Ottinger,Nicole Y. Farhat,Kelly A. King,Xuntian Jiang,Lisa Weissfeld,Elizabeth Berry-Kravis,Cristin Davidson,Simona Bianconi,Lee Ann Keener,Ravichandran Rao,Ariane Soldatos,Rohini Sidhu,Kimberly A Walters,Xin Xu,Audrey Thurm,Beth Solomon,William J. Pavan,Bernardus Nicolaas Machielse,Mark L. Kao,Steven A. Silber,John C. McKew,Carmen C. Brewer,Charles H. Vite,Steven U. Walkley,Christopher P. Austin,Forbes D. Porter +26 more
TL;DR: This open-label, dose-escalation phase 1-2a study gave monthly intrathecal HPβCD to participants with NPC1 with neurological manifestation at the National Institutes of Health and evaluated Serum and CSF 24(S)-hydroxycholesterol (24[S]-HC), which serves as a biomarker of target engagement, andCSF protein biomarkers were evaluated.
Journal ArticleDOI
A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma
Xuntian Jiang,Rohini Sidhu,Forbes D. Porter,Nicole M. Yanjanin,Anneliese O. Speak,Danielle Taylor te Vruchte,Frances M. Platt,Hideji Fujiwara,David E. Scherrer,Jessie Zhang,Dennis J. Dietzen,Jean E. Schaffer,Daniel S. Ory +12 more
TL;DR: The development of a sensitive and specific LC-MS/MS method for quantifying 3β,5α,6β-triol and 7-KC human plasma after derivatization with N,N-dimethylglycine is described, offering for the first time a noninvasive, rapid, and highly sensitive method for diagnosis of NPC1 disease.
Journal ArticleDOI
ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signalling in Niemann-Pick type C.
Chun Yan Lim,Oliver B. Davis,Hijai R. Shin,Justin Zhang,Charles A. Berdan,Xuntian Jiang,Jessica L. Counihan,Daniel S. Ory,Daniel K. Nomura,Roberto Zoncu +9 more
TL;DR: ER–lysosome contacts are signalling hubs that enable cholesterol sensing by mTORC1, and targeting the sterol-transfer activity of these signalling hubs could be beneficial in patients with NPC.
Journal ArticleDOI
Ceramide remodeling and risk of cardiovascular events and mortality
Linda R. Peterson,Vanessa Xanthakis,Meredith S. Duncan,Stefan Gross,Nele Friedrich,Henry Völzke,Stephan B. Felix,Hui Jiang,Rohini Sidhu,Matthias Nauck,Xuntian Jiang,Daniel S. Ory,Marcus Dörr,Ramachandran S. Vasan,Jean E. Schaffer +14 more
TL;DR: The ratio of C24:0/C16:0 ceramides in blood may be a valuable new biomarker of CHD risk, HF risk, and all‐cause mortality in the community.